grants_govPAR-25-321
Open
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
- Response deadline
- Jan 7, 2028 Due in 448 days
- Date posted
- Dec 10, 2024
- Source
- Open notice
Description
Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.
Classifications
- NAICS93.394
Documents (1)
- DownloadPAR-25-321-Full-Announcement.htmltext/html422 B
Contacts
- grantsinfo@nih.gov301-402-2541
Similar contracts
- Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)Due Feb 11, 2027
- Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)Due Jan 11, 2027
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)Due Nov 10, 2026
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)Due Nov 10, 2026
- Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)Due Jan 7, 2028
- Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)Due Jan 7, 2028